Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

24.32 -2.74 (-10.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,722,631
Open 26.72
Bid (Size) 25.45 (6)
Ask (Size) 26.50 (1)
Prev. Close 27.06
Today's Range 24.24 - 28.73
52wk Range 13.48 - 39.77
Shares Outstanding 956,637,360
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why ZAI LAB LTD-ADR (NASDAQ:ZLAB) could fit Mark Minervini’s high-growth criteria
A fundamental and technical analysis of (NASDAQ:ZLAB): Why the high growth investor may take a look at ZAI LAB LTD-ADR (NASDAQ:ZLAB). 
Via Chartmill
No Fear And No Panic After A 10% Correction = No Bottom
In this video lesson, I discuss the overall market, my books, and my game plan moving forward after Friday's ugly sell-off. 
Via Talk Markets
Topics Stocks / Equities

Performance

YTD
-2.0%
-2.0%
1 Month
-31.2%
-31.2%
3 Month
-3.9%
-3.9%
6 Month
-4.0%
-4.0%
1 Year
+57.9%
+57.9%

More News

Read More
Argan Posts Upbeat Results, Joins KULR Technology, Abacus Global Management, W. R. Berkley And Other Big Stocks Moving Higher On Friday
Via Benzinga
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Participation in Investor Conferences in March 2025
From Zai Lab Limited
Via Business Wire
NovoCure Q4 EPS Misses, Revenue Matches
Via The Motley Fool
Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
From Zai Lab Limited
Via Business Wire
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Participation in Investor Conference in January 2025
From Zai Lab Limited
Via Business Wire
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?
Via The Motley Fool
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
Via Benzinga
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
From Zai Lab
Via Business Wire
Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List
From Zai Lab Limited
Via Business Wire
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
From Zai Lab
Via Business Wire
Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
From Zai Lab Limited
Via Business Wire

Frequently Asked Questions

Is Zai Lab Limited - American Depositary Shares publicly traded?
Yes, Zai Lab Limited - American Depositary Shares is publicly traded.
What exchange does Zai Lab Limited - American Depositary Shares trade on?
Zai Lab Limited - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Zai Lab Limited - American Depositary Shares?
The ticker symbol for Zai Lab Limited - American Depositary Shares is ZLAB on the Nasdaq Stock Market
What is the current price of Zai Lab Limited - American Depositary Shares?
The current price of Zai Lab Limited - American Depositary Shares is 24.32
When was Zai Lab Limited - American Depositary Shares last traded?
The last trade of Zai Lab Limited - American Depositary Shares was at 04/10/25 04:00 PM ET
What is the market capitalization of Zai Lab Limited - American Depositary Shares?
The market capitalization of Zai Lab Limited - American Depositary Shares is 23.27B
How many shares of Zai Lab Limited - American Depositary Shares are outstanding?
Zai Lab Limited - American Depositary Shares has 23B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.